source
- FDA advisory panel rejects Capricor’s Duchenne cardiomyopathy cell therapyA FDA advisory committee voted against Capricor’s cell therapy for Duchenne muscular dystrophy cardiomyopathy, with nine members opposing and three supporting the product. The therapy, called dera…
- Novo Nordisk loses bid to dismiss lawsuit over CagriSema trial readoutU.S. District Judge Robert Kirsch in New Jersey refused to dismiss most of the securities lawsuit filed by investors after Novo Nordisk’s CagriSema readout. While the judge found the plaintiffs’ cl…